Latest News & Features
Refine Search
Europe
Law firm King & Spalding has appointed a partner to its office in Washington, DC. 10 December 2014
Americas
Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept). 9 December 2014
Americas
A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds. 8 December 2014
Americas
US research centre the Broad Institute of Massachusetts Institute of Technology and Harvard has entered into a worldwide licensing deal with Editas Medicines, granting it access to IP covering genome technology and human therapeutic applications. 5 December 2014
Americas
The US Court of Appeals for the Federal Circuit has overturned a decision on patent claims for a drug used to treat anorexia and cachexia in AIDS patients. 4 December 2014
Americas
Drugs companies Cipla and Meda Pharmaceuticals have sued Canada-based Apotex as they seek to protect the nasal spray Dymista (Azelastine hydrochloride, fluticasone propionate). 3 December 2014
Asia-Pacific
Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes. 2 December 2014
Big Pharma
Nearly 170,000 counterfeit medicinal items have been seized following a police raid in Hungary. 1 December 2014
Big Pharma
By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line. 28 November 2014
Genetics
Does the coming into force of the Nagoya Protocol represent an overdue step in the right direction towards fairness, or more red tape and unattainable expectations? Charles Brabin, a non-practising barrister, sifts through the complexities. 28 November 2014